BD Acquires Dose Innovations Sales and Support Operations for Rowa Technologies in Australia, New Zealand

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of assets from Dose Innovations Pty. Ltd. that sell and support BD Rowa™ Technologies in Australia and New Zealand.

Dirk Wingenter, vice president of Rowa Technologies for BD said, “By taking over the sales and service operations of Dose Innovations that supported Rowa Technologies solutions in Australia and New Zealand, BD can more quickly build scale and depth in medication dispensing solutions for community pharmacies, pharmacy banner groups, hospital pharmacies and pharmaceutical wholesalers. We look forward to enhancing the pharmacy experience and innovations in medication wholesale across Australia and New Zealand.”

 

The transaction follows a licensing agreement between BD and Dose Innovations and its voluntary administrator that has been in place since January 2018 that ensured continuity of sales and support for BD Rowa™ products and other services provided by Dose Innovations under BD distribution agreements. The acquisition provides a long-term solution and business continuity for BD Rowa customers. 

 

Financial terms of the transaction were not disclosed. 

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. 

 

BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. 

 

For more information on BD, please visit bd.com.